Trial Profile
Phase II study of BAY 43-9006 in patients with metastatic thyroid carcinoma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 15 Jan 2014 Actual end date changed from 1 Oct 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 03 Jun 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 24 Jan 2012 Planned End Date 1 Dec 2011 added as reported by ClinicalTrials.gov.